FDA tells Endo to remove Opana ER from the market

8th June 2017 Uncategorised 0

The FDA has asked Endo Pharmaceuticals to remove opioid painkiller Opana ER from the market, saying that in the midst of an opioid addiction crisis, its risks outweigh its benefits. The FDA warned that if Endo chose not to, it would take steps to require removal from the market.

More: FDA tells Endo to remove Opana ER from the market
Source: fierce